Bathing Babies and Allergy
NCT03050658
Recruiting
Atopic dermatitis (AD) is a chronic allergic skin disease with onset in early childhood and increasing prevalence in Westernized countries. Current well newborn guidelines for washing babies with soap were adopted by U.S. hospitals in the 1970s, before the rise in prevalence of allergic disease and AD (also called eczema). Increased transepidermal water-loss (TEWL) in newborn skin at 2 days of life was recently identified as a predictor of AD and allergy development by age 2 years. Risk for AD i... Read More
Gender:
All
Ages:
72 hours and below
Trial Updated:
02/10/2017
Locations: University of Virginia Health System, Charlottesville, Virginia
Conditions: Atopic Dermatitis, Allergy
Register for Updates
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
NCT05882877
Recruiting
The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.
Gender:
All
Ages:
Between 12 years and 100 years
Trial Updated:
11/29/2023
Locations: Cahaba Dermatology and Skin Health Center, Birmingham, Alabama +144 locations
Conditions: Atopic Dermatitis
Register for Updates
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
NCT05601882
Recruiting
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study compares upadacitinib to dupilumab in adolescent and adult participants with moderate to severe AD who have inadequate response to systemic therapies. Adverse events and change in the disease activity will be assessed. Upadacitinib and dup... Read More
Gender:
All
Ages:
Between 12 years and 64 years
Trial Updated:
11/28/2023
Locations: Medical Dermatology Specialist /ID# 250212, Phoenix, Arizona +256 locations
Conditions: Atopic Dermatitis
Register for Updates
Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis
NCT06144424
Recruiting
This Phase 2a trial will evaluate the effects of EP262 in subjects with atopic dermatitis
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
11/28/2023
Locations: Allervie Clinical Research, Birmingham, Alabama +9 locations
Conditions: Atopic Dermatitis
Register for Updates
Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe Atopic Dermatitis
NCT06101823
Recruiting
The purpose of this study is to determine the efficacy and safety of a monoclonal antibody, OpSCF, in the treatment of adults with moderate to severe Atopic Dermatitis (Eczema). OpSCF will be compared to a placebo. OpSCF or placebo will be administered every 2 weeks for 14 weeks, and the efficacy will be assessed two weeks later. After that, subjects may choose to enter an Open Label Extension phase in which all subjects will receive OpSCF every 4 weeks for 40 additional weeks.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
11/24/2023
Locations: Cahaba Dermatology & Skin Health Center, Birmingham, Alabama +15 locations
Conditions: Atopic Dermatitis
Register for Updates
A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)
NCT05277571
Recruiting
The purpose of the study is to investigate the safety and tolerability of single-ascending doses of UCB1381 (intravenous and subcutaneous) in healthy study participants and after repeat intravenous dosing in study participants with atopic dermatitis. Efficacy will be assessed following repeat intravenous dosing versus placebo in study participants with atopic dermatitis.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
11/23/2023
Locations: Up0110 117, North Little Rock, Arkansas +22 locations
Conditions: Atopic Dermatitis
Register for Updates
A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
NCT05633355
Recruiting
The primary objective of this study is to describe the safety and tolerability of rocatinlimab in adolescents with moderate-to-severe AD.
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
11/22/2023
Locations: Phoenix Childrens Hosptial, Phoenix, Arizona +59 locations
Conditions: Atopic Dermatitis
Register for Updates
A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)
NCT05651711
Recruiting
The co-primary objectives of the study are to: Evaluate the efficacy of rocatinlimab compared with placebo at Week 24, assessed using Validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD). Evaluate the efficacy of rocatinlimab compared with placebo at Week 24, assessed using Eczema Area and Severity Index (EASI).
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
11/22/2023
Locations: Research Solutions of Arizona, PC, Litchfield Park, Arizona +196 locations
Conditions: Atopic Dermatitis
Register for Updates
Studies of Skin Microbes in Healthy People and in People With Skin Conditions
NCT00605878
Recruiting
This study will examine microbes (e.g., bacteria, fungi, viruses) that live on human skin and how microbes contribute to health and disease. It will analyze healthy human skin and how the these microorganisms might change in patients with atopic dermatitis (AD), a skin condition also known as eczema. Healthy volunteers, as well as patients with moderate to severe eczema (AD), between 2 and 40 years of age may be eligible for this study. We also wish to enroll children and adults aged 2-40 who... Read More
Gender:
All
Ages:
Between 2 years and 100 years
Trial Updated:
11/17/2023
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Atopic Dermatitis, Eczema, Ichthyosis Vulgaris
Register for Updates
A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)
NCT05398445
Recruiting
The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy treatment.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
11/15/2023
Locations: Cahaba Dermatology and Skin Health Center, Birmingham, Alabama +178 locations
Conditions: Atopic Dermatitis
Register for Updates
A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)
NCT05899816
Recruiting
The primary objectives of this study are to: estimate vaccine response in rocatinlimab group vs placebo group, assessed using antibody anti-tetanus response at Week 24 estimate vaccine response in rocatinlimab group vs placebo group, assessed using antibody anti-meningococcal response at Week 24
Gender:
All
Ages:
Between 18 years and 54 years
Trial Updated:
11/15/2023
Locations: Affiliated Dermatology, Scottsdale, Arizona +55 locations
Conditions: Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis
Register for Updates
A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)
NCT05724199
Recruiting
The coprimary objectives of the study are to: evaluate the efficacy of rocatinlimab in combination with topical corticosteroid and/or topical calcineurin inhibitor (TCS/TCI), compared with placebo in combination with TCS/TCI at Week 24, assessed using Validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD™). evaluate the efficacy of rocatinlimab, in combination with TCS/TCI, compared with placebo in combination with TCS/TCI at Week 24, assessed using Eczema Area and Severity... Read More
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
11/15/2023
Locations: The University of Alabama at Birmingham, Birmingham, Alabama +199 locations
Conditions: Atopic Dermatitis
Register for Updates